Perspectives on the Barrier to Resistance for Dolutegravir + Lamivudine, a Two-Drug Antiretroviral Therapy for HIV-1 Infection
In HIV-1-infected patients, virological failure can occur as a consequence of the mutations that accumulate in the viral genome that allow replication to continue in the presence of antiretrovirals (ARVs). The development of treatment-emergent resistance to an ARV can limit a patient's options for future therapy, prompting the need for ARV regimens that are resilient to the emergence of resistance. The genetic barrier to resistance refers to the number of mutations in an ARV's therapeutic target that are required to confer a clinically meaningful loss of susceptibility to the drug. The emergence of resistance can be affected by pharmacological aspects of the ARV, including its structure, inhibitory quotient, therapeutic index, and pharmacokinetic characteristics. Dolutegravir (DTG) has demonstrated a high barrier to resistance, including when used in a two-drug regimen (2DR) with lamivudine (3TC). In the GEMINI-1 and GEMINI-2 studies, DTG +3TC was noninferior to DTG + emtricitabine/tenofovir disoproxil fumarate in treatment-naive participants, with similar proportions achieving HIV-1 RNA <50 copies/mL through 96 weeks. Furthermore, in the TANGO study, virological suppression was maintained at 48 weeks after switching to DTG +3TC from a tenofovir alafenamide (TAF)-based regimen compared with continuing a TAF-based regimen. Most other 2DRs with successful outcomes compared with three-drug regimens have been based on protease inhibitors (PIs); however, this class is associated with adverse metabolic effects and drug-drug interactions. In this review, we discuss the barrier to resistance in the context of a 2DR in which a boosted PI is replaced with DTG +3TC.
| Errataetall: |
CommentIn: AIDS Res Hum Retroviruses. 2020 Apr;36(4):254-255. - PMID 31914799 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:36 |
|---|---|
| Enthalten in: |
AIDS research and human retroviruses - 36(2020), 1 vom: 03. Jan., Seite 13-18 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Boffito, Marta [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 09.12.2020 Date Revised 14.12.2020 published: Print-Electronic CommentIn: AIDS Res Hum Retroviruses. 2020 Apr;36(4):254-255. - PMID 31914799 Citation Status MEDLINE |
|---|
| doi: |
10.1089/AID.2019.0171 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM301159041 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM301159041 | ||
| 003 | DE-627 | ||
| 005 | 20231225104042.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1089/AID.2019.0171 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1003.xml |
| 035 | |a (DE-627)NLM301159041 | ||
| 035 | |a (NLM)31507204 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Boffito, Marta |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Perspectives on the Barrier to Resistance for Dolutegravir + Lamivudine, a Two-Drug Antiretroviral Therapy for HIV-1 Infection |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.12.2020 | ||
| 500 | |a Date Revised 14.12.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: AIDS Res Hum Retroviruses. 2020 Apr;36(4):254-255. - PMID 31914799 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a In HIV-1-infected patients, virological failure can occur as a consequence of the mutations that accumulate in the viral genome that allow replication to continue in the presence of antiretrovirals (ARVs). The development of treatment-emergent resistance to an ARV can limit a patient's options for future therapy, prompting the need for ARV regimens that are resilient to the emergence of resistance. The genetic barrier to resistance refers to the number of mutations in an ARV's therapeutic target that are required to confer a clinically meaningful loss of susceptibility to the drug. The emergence of resistance can be affected by pharmacological aspects of the ARV, including its structure, inhibitory quotient, therapeutic index, and pharmacokinetic characteristics. Dolutegravir (DTG) has demonstrated a high barrier to resistance, including when used in a two-drug regimen (2DR) with lamivudine (3TC). In the GEMINI-1 and GEMINI-2 studies, DTG +3TC was noninferior to DTG + emtricitabine/tenofovir disoproxil fumarate in treatment-naive participants, with similar proportions achieving HIV-1 RNA <50 copies/mL through 96 weeks. Furthermore, in the TANGO study, virological suppression was maintained at 48 weeks after switching to DTG +3TC from a tenofovir alafenamide (TAF)-based regimen compared with continuing a TAF-based regimen. Most other 2DRs with successful outcomes compared with three-drug regimens have been based on protease inhibitors (PIs); however, this class is associated with adverse metabolic effects and drug-drug interactions. In this review, we discuss the barrier to resistance in the context of a 2DR in which a boosted PI is replaced with DTG +3TC | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a HIV | |
| 650 | 4 | |a antiretroviral | |
| 650 | 4 | |a genetic barrier to resistance | |
| 650 | 4 | |a integrase strand transfer inhibitor | |
| 650 | 4 | |a two-drug regimen | |
| 650 | 7 | |a Anti-Retroviral Agents |2 NLM | |
| 650 | 7 | |a Heterocyclic Compounds, 3-Ring |2 NLM | |
| 650 | 7 | |a Oxazines |2 NLM | |
| 650 | 7 | |a Piperazines |2 NLM | |
| 650 | 7 | |a Pyridones |2 NLM | |
| 650 | 7 | |a RNA, Viral |2 NLM | |
| 650 | 7 | |a Lamivudine |2 NLM | |
| 650 | 7 | |a 2T8Q726O95 |2 NLM | |
| 650 | 7 | |a dolutegravir |2 NLM | |
| 650 | 7 | |a DKO1W9H7M1 |2 NLM | |
| 700 | 1 | |a Waters, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Cahn, Pedro |e verfasserin |4 aut | |
| 700 | 1 | |a Paredes, Roger |e verfasserin |4 aut | |
| 700 | 1 | |a Koteff, Justin |e verfasserin |4 aut | |
| 700 | 1 | |a Van Wyk, Jean |e verfasserin |4 aut | |
| 700 | 1 | |a Vincent, Tia |e verfasserin |4 aut | |
| 700 | 1 | |a Demarest, James |e verfasserin |4 aut | |
| 700 | 1 | |a Adkison, Kimberly |e verfasserin |4 aut | |
| 700 | 1 | |a Quercia, Romina |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t AIDS research and human retroviruses |d 1990 |g 36(2020), 1 vom: 03. Jan., Seite 13-18 |w (DE-627)NLM012611727 |x 1931-8405 |7 nnns |
| 773 | 1 | 8 | |g volume:36 |g year:2020 |g number:1 |g day:03 |g month:01 |g pages:13-18 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1089/AID.2019.0171 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 36 |j 2020 |e 1 |b 03 |c 01 |h 13-18 | ||